Bioverativ, A Sanofi Company

This early-phase study tested a single dose of BIVV020 in 12 adults with cold agglutinin disease, a rare condition where the immune system attacks red blood cells in cold temperatures. The main goal was to check safety and tolerability, while also measuring effects on blood cell …

This study tested a new drug called SAR445088 in 98 adults with CIDP, a nerve disorder that causes weakness and numbness. The goal was to see if the drug could help control the disease in people who are on standard treatment, have not responded to standard treatment, or have neve…

This study tested a new medicine called BIVV001 in 159 people aged 12 and older with severe hemophilia A. The goal was to see if regular injections could prevent bleeding episodes and improve joint health and quality of life. Results showed the treatment helped control bleeds, bu…

This study tested a new medicine called BIVV001 in 74 children under 12 with severe hemophilia A, a condition where blood doesn't clot properly. The goal was to see if the drug is safe and can help prevent or control bleeding episodes. The children received regular infusions of t…

This study tested an experimental drug called BIVV020 in 12 adults with persistent or chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding and bruising. The goal was to see if the drug could safely raise and maintain plat…

This early-stage study tested a single injection of a new drug called BIVV001 in 6 adults with type 2N or 3 von Willebrand disease, a rare bleeding disorder. The main goals were to see how the drug behaves in the body and whether it is safe. The study was completed, but results a…